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In the initial treatment of acute myocardial infarction, it is important to 
administer oral low-dose acetylsalicylic acid (ASA) within 10 min of arrival 
at the hospital. However, ASA is supplied as an enteric-coated tablet or 
buffered tablet to prevent gastric irritation. Although current guidelines 
recommended that patients should chew their initial dose of ASA, there is 
little evidence as to whether this is efficacious. Therefore, we aimed to make 
a direct comparison of the pharmacokinetics and pharmacodynamics of ASA 
after ingestion of intact and chewed non-enteric-coated buffered ASA tablet 
(NBA) and enteric-coated ASA tablet (ECA) in a quadruple crossover study 
in healthy volunteers. Chewing ECA accelerated tmax of ASA absorption, 
which became equivalent to that after ingestion of intact or chewed NBA. A 
significant decrease in serum thromboxane B2 was observed 20 min after 
ingestion of chewed ECA, or intact or chewed NBA, and inhibition of platelet 
aggregation was also observed within 20 min. Thus, chewing of the ECA 
appears to result in a similar timing of ASA action to that in the case of 




Acetylsalicylic acid (ASA) irreversibly acetylates and inactivates platelet 
cyclooxygenase (COX), which catalyzes the first step in the conversion of 
arachidonic acid to thromboxane A2.1-6 Thromboxane A2 stimulates platelet 
recruitment, activation, aggregation and vasoconstriction. The ASA-induced 
inhibition lasts for the life of the platelet, or about 7-10 days.7-8 At the same 
time, inactivation of COX in vascular endothelial cells also prevents the 
synthesis of prostacyclin a substance that inhibits platelet aggregation. 
Endothelial cells can recover COX activity by biosynthesis, but platelets do 
not synthesize new COX.5 Thus, though oral ASA 325-650 mg every 4-6 hr 
exhibits analgesic and antipyretic effects, and 3.6-5.4 g/day exhibits an 
anti-inflammatory effect, low-dose ASA exhibits an antiplatelet effect. 
Chronic inhibition of platelet activity may be achieved with daily dose of 80 
mg ASA9. Many clinical trials have demonstrated that low-dose ASA once 
daily is clinically effective in prevention and treatment of myocardial 
infarction, acute ischemic stroke and transient cerebral ischemia, and as 
adjunctive therapy in revascularization procedures such as coronary artery 
bypass grafting, percutaneous transluminal coronary angioplasty, carotid 
endarterectomy and stent implantation.10-20  
The major side-effect of ASA is gastric irritation. So, ASA is 
available as sustained-release, enteric-coated tablet dosage forms or as 
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non-coated buffered tablets. Enteric coating prevents the release of free 
aspirin until after the tablet has left the stomach.21 Buffered ASA tablets 
contain di-aluminate or other buffer species that protect the stomach mucosa 
from irritation. ASA in enteric-coated tablets is absorbed much more slowly 
than ASA in buffered tablets, resulting in low plasma ASA levels.22 These 
dosage forms should not be crushed or chewed to prevent gastric irritation 
for general use. 
 On the other hand, the time of initiation of treatment is important 
in patients with acute myocardial infarction, such as ST-segment-elevation 
myocardial infarction. The Guidelines for the management of patients with 
ST-elevation myocardial infarction recommend starting MONA (morphine, 
oxygen, nitric oxide and aspirin) treatment within 10 min of arrival at the 
hospital.23,24 As the use of morphine is difficult in some clinical situations, 
isosorbide dinitrate is often administered sublingually or as an oral spray 
and low-dose ASA is orally administered as soon as possible. Under these 
circumstances, however, immediate absorption and action of ASA are very 
important, and so it has been recommended that patients should chew the 
tablets. However, this recommendation does not yet have an adequate 
evidential basis. 
 The pharmacokinetic as well as pharmacological characteristics of 
enteric-coated, plain non-enteric-coated buffered ASA tablet and soluble ASA 
after normal ingestion have been clarified,7,8,22,25-29 but there has been no 
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direct comparison with the characteristics after ingestion of chewed low-dose 
ASA tablets. Therefore, the aim of the present study was to provide clinical 
evidence to support the recommendation of the Guidelines for the 
management of patients with acute myocardial infarction. Specifically, we 
aimed to clarify the pharmacokinetics of ASA and the immediate effect on 
platelet aggregation and serum thromboxane A2 level following ingestion of 
compressed non-enteric coated buffered tablet (NBA) and enteric-coated 








Bufferin® 81 mg Tablets (non-enteric coated buffered acetylsalicylic acid 
tablet, NBA)) and Bayaspirin® 100 mg Enteric-Coated Aspirin Tablets 
(ECA) were purchased from Eisai Co., Ltd. (Tokyo, Japan) and Bayer 
Yakuhin, Ltd. (Osaka, Japan), respectively. Thromboxane EIA Kit was from 
Cayman Chemical Company (Ann Arbor, MI).  2-Methylbenzoic acid and 
blank human serum were purchased from Wako Pure Chemical Industries, 
Ltd. (Osaka, Japan) and Sigma-Aldrich (St. Louis, MO), respectively. All 
other chemicals were commercial products of reagent grade or HPLC grade, 
and were used without further purification. 
 
Study Design and Subjects 
 
 Volunteers were required to meet the following inclusion criteria: 1) aged 20 to 50 
years, of either sex, 2) exhibited normal platelet aggregation, and 3) gave written 
informed consent. Exclusion criteria were: 1) a history of hypersensitivity to ingredients 
of Bufferin 81 mg tablet, Bayaspirin 100 mg or other salicylic acid formulations, 2) a 
history of aspirin asthma, 3) use of non-steroidal anti-inflammatory drugs (NSAIDs) 
within the previous 2 weeks, 4) administration of an anti-platelet agent within the 
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previous 2 weeks, 5) administration of an anti-coagulation drug within the previous 2 
weeks, 6) scheduled to receive odontectomy or other invasive operation within 2 weeks, 
7) diagnosed with peptic ulcer, 8) pregnant, in parturition or lactating, 9) a bleeding 
tendency, 10) in hypermenorrhea, 11) drinking alcohol on a regular basis, 12) any other 
situation that the doctor deemed inappropriate for inclusion. To determine whether or 
not volunteers met the above inclusion and exclusion criteria, we requested them to 
complete a medical interview sheet, and further medical examination was carried out by 
a physician when this was considered necessary. Six male and 6 female healthy 
volunteers aged 20–34 years participated in this study. The subjects did not 
ingest aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) for 
at least two weeks prior to the start of the study, or prior to the re-start of 
subsequent parts of the study, and also refrained from drinking alcohol for at 
least 24 hr. In addition, volunteers were screened for baseline platelet 
aggregation, using a blood sample taken just before ingestion of ASA, in 
order to confirm that none showed abnormal aggregation. We employed a 
randomized, single-dose, quadruple-crossover design. Each subject ingested 
intact or chewed (2 or 3 times within 5 seconds) NBA or ECA with a glass of 
water. Each subject had the same lean breakfast 1 hr prior to ASA ingestion. 
Thereafter, food was not permitted until the end of each part of the study. 
The four study periods were all separated by washout periods of at least two 
weeks. Water and tea were allowed throughout the study. Venous blood 
samples were obtained without stasis by using a 21-gauge needle or catheter 
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with a 3-way stopcock filled with isotonic saline. A 4 mL sample was collected 
in a vacuum blood collection tube. For acetylsalicylic acid, salicylic acid and 
thromboxane B2 determinations, the sera were separated by centrifugation, 
then frozen and stored at -80°C until required for analysis. For platelet 
aggregation studies, a 2.7 mL sample of whole blood was collected in a 
vacuum blood collection tube containing 0.3 mL of 3.13% sodium citrate (9:1 
vol:vol) and used immediately. The sampling was performed at 5 min before 
and 5, 10, 20, 30, 60, 120, 240, 360 and 480 min after tablet ingestion. All 
subjects provided written informed consent prior to participation. This study 
protocol was approved by the Institutional Review Board of Kanazawa 
University Hospital (approval number: 2009-028 (5584)).  
 
Estimation of Serum ASA and SA 
 
Serum ASA and SA concentrations were determined according to the method 
reported by Kees et al.30 The HPLC system consisted of a Shimadzu 
LC-10ADvp pump (Shimadzu, Tokyo, Japan), SIL-10ADvp injector, 
CTO-10ASvp column oven, SPD-10Avp UV detector, SCL-10Avp system 
controller, and C-R8A Chromatopack. The analytical column was a Nova-Pak 
C18 3.9 x 150 mm 4 μm column from Waters (Milford, MA). The HPLC 
separation module was operated under the following conditions: sample 
temperature, 4°C; analytical column temperature, 30ºC; sample injection 
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volume, 20 μL. The mobile phase consisted of 740 mL water, 900 μL 
orthophosphoric acid (85%) and 180 mL acetonitrile, and was delivered at 1.0 
mL/min. The detection wavelength was set at 237 nm. The precision and 
accuracy were evaluated using two samples each at four (ASA) or three (SA) different 
concentrations for 17 days. The mean overall values of calculated accuracy and 
precision (percent) for each concentration over 17 days were 100 ± 10 % with a %CV of 
21% and 100 ± 8.3 % with a %CV of 1.7 % for ASA and SA, respectively. The lower 
limit of quantitation was 80 ng/mL for ASA and 50 ng/mL for SA. All concentrations 
below the limits of quantitation of the assay were taken to be zero. 




The area under the serum ASA and SA concentration versus time curves up 
to the last sampling time AUC0-8 (μg·hr/mL) were calculated according to the 
linear trapezoidal method. The mean residence time (MRT) was calculated 
as AUMC divided by AUC, where AUMC is the area under the fist moment 
curve.  
 
Thromboxane A2 Determination 
 
Serum thromboxane A2 was determined by enzyme-immunoassay of its 
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stable metabolite thromboxane B2 (Thromboxane B2 EIA Kit, Cayman 





Blood samples were centrifuged at 1,000 rpm for 15 min to obtain 
platelet-rich plasma, which was transferred to a polystyrene tube with a 
pipette. Platelet-poor plasma was obtained by further centrifugation at 3,000 
rpm for 15 min. Aggregometry was performed using a PAM-8T Aggregometer 
(Mebanics Inc, Tokyo, Japan). The aggregometer was adjusted before each 
measurement so that platelet-rich plasma gave no light transmission and 
platelet-poor plasma gave 100% light transmission. Collagen (Hormon 
Chemie, Munich, Germany) and ADP (MCM) were used as aggregating 
agents. The maximum platelet aggregation (%) was determined by 
aggregation tracing for 5 min for each blood sample obtained before and after 
ingestion of ASA. Inhibition of platelet aggregation following ASA ingestion 
was evaluated as a percentage of to the maximum platelet aggregation 





Statistical analysis was performed by analysis of variance (ANOVA) with 
Tukey’s and Dunnett's post-hoc tests, using GraphPad PRISM version 5.02 





Serum Concentration-Time Profiles of Acetylsalicylic Acid and Salicylic Acid 
after Ingestion of Intact and Chewed NBA and ECA.  
Twelve healthy volunteers each received four separate oral drug 
administrations, i.e., intact and chewed NBA and intact and chewed ECA. 
One volunteer withdrew in the middle of blood sampling after ingestion of 
intact ECA because of vascular pain owing to multiple venous punctures. 
Another volunteer withdrew in the middle of the intact ECA period because 
of feeling unwell, and also retracted her consent to participate in the period 
of chewed ingestion of NBA. Figures 1 and 2 illustrate the serum 
concentration-time profiles of acetylsalicylic acid (ASA) and salicylic acid 
(SA), respectively.  
 ASA was detectable in the serum of 8 out of 12 volunteers within 20 
min after ingestion of intact NBA, although significant inter-individual 
variability was observed (Fig. 1). The concentration of ASA increased rapidly 
and peaked at 1 hr after ingestion. After ingestion of intact ECA, ASA was 
not detectable in serum until 4 hr. When ECA was chewed, ASA was 
detectable in 8 out of 12 volunteers within 20 min after ingestion. Chewing of 
the NBA did not significantly affect the appearance of ASA compared with 
that after ingestion of intact NBA.  
 The mean serum SA concentration peaked at 2 hr after ingestion of 
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intact or chewed NBA (Fig. 2). SA was not detectable until 2 hr after the 
ingestion of intact ECA, but when ECA was chewed, SA peaked at 2 hr after 
ingestion (Fig. 2). Chewing of the NBA did not significantly affect the 
appearance of SA compared with intact NBA.  
 The pharmacokinetic parameters of ASA and SA are summarized in 
Table 1. The MRT of ASA was 1.9 ± 0.9 hr (mean ± S.D., n = 12) and 6.8 ± 1.3 
hr (n = 10) after ingestion of NBA and ECA, respectively. Chewing ECA 
greatly shortened the MRT to 2.4 ± 1.2 hr (n = 12). 
 
Effect of Ingestion of Intact and Chewed NBA and ECA on Serum 
Thromboxane B2 Level 
Table 2 summarizes the effects of ingestion of intact and chewed NBA and 
ECA on serum thromboxane B2 levels (TXB2). As baseline serum TXB2 levels 
varied greatly among volunteers, the effect of ASA on TXB2 was expressed as 
a percentage of the baseline TXB2 value measured before ingestion for each 
volunteer. A significant decrease in TXB2 was observed at 20 min after 
ingestion of intact NBA (Table 2), but not until 8 hr after ingestion of intact 
ECA, although average TXB2 was decreased to less than 50% after 4 hr 
(Table 2). When ECA was chewed, the decrease in TXB2 after 20 min was 
comparable to that in the case of intact NBA. When NBA was chewed, the 
average TXB2 was decreased to less than 60% and the decrease reached 
statistical significance after 1 hr.  
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Effect of Ingestion of Intact and Chewed NBA and ECA on Platelet 
Aggregation 
We employed two different aggregating agents, collagen and ADP. ADP at 2 
μM induces primary and secondary aggregation while 1 μg/mL collagen 
induces secondary aggregation of platelets. ASA is expected to have a much 
stronger inhibitory effect on secondary aggregation. 
 Table 3 summarizes the effect of ingestion of intact and chewed 
NBA and ECA on platelet aggregation induced with 1 μg/mL collagen. The 
aggregation was inhibited significantly within 20 min after ingestion of 
intact NBA (Table 3), but no effect was observed until 4 hr after ingestion of 
intact ECA. When ECA was chewed, inhibition of platelet aggregation was 
observed after 20 min, as in the case of intact NBA. Chewing NBA had little 
effect on inhibition of platelet aggregation, compared with the intact tablet. 
The effect of ASA on platelet aggregation was also evaluated using 2 μM 
ADP as the aggregating agent (Table 4). In this case, platelet aggregation 




The FDA approved general ASA formulations as an antiplatelet drug in 1998. 
In Japan, “Baby Bufferin”, which contained 81 mg ASA at that time, and 
Bayaspirin 100 mg Tablet were used as off-label pharmaceuticals before 
1999, when Ministry of Health, Labour and Welfare, Japan approved their 
use. These approvals were not based on a new clinical trial, but were based 
on literature data. Indeed, the ACC/AHA (the American College of 
Cardiology and the American Heart Association) and Japanese Guidelines 
for the Management of Patients with Acute Myocardial Infarction23,24 were 
largely based on results from the ISIS-2 study (Second International Study 
of Infarct Survival),13 where the patients ingested 162.5 mg enteric-coated 
tablets that were crushed, sucked or chewed to achieve a rapid effect. 
However, there has been no comprehensive clinical study showing that 
crushing, sucking or chewing ASA tablet actually accelerates the absorption 
and antiplatelet effect compared with ingestion of the intact preparations. 
Nonetheless, patients with myocardial infarction are customarily instructed 
to chew their initial dose of ASA, and current guidelines have encouraged 
this practice. In order to obtain evidence for the efficacy of this practice, we 
designed a quadruple-crossover study in 12 healthy volunteers to directly 
compare the pharmacokinetics and pharmacodynamics of NBA and ECA 
ingested intact or after chewing.  
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 Chewing of the ECA greatly accelerated tmax and MRT of ASA (Fig. 1 
and Table 1). The tmax (1.4 hr) and Cmax (198 ng/mL) were comparable to 
those after ingestion of intact NBA (0.9 hr and 174 ng/mL, respectively). 
Significant decrease of TXB2 and inhibition of platelet aggregation were 
observed at 20 min after ingestion of chewed ECA, or intact or chewed NBA. 
The results indicate that platelet COX was inhibited within 20 min after 
ingestion of chewed ECA as was also the case after ingestion of intact or 
chewed NBA (Tables 3 and 4). Thus, inhibition of COX was achieved before 
the serum ASA level peaked. Schwertner et al have suggested that a plasma 
salicylate concentration of 2.46 μg/mL is required to inhibit platelet 
aggregation.29 But, as the anti-platelet effect of ASA results from irreversible 
acetylation of COX and inhibition of thromboxane A2 production, the 
acetylsalicylic acid concentration rather than the salicylic acid concentration 
would be important for anti-platelet effect. In this study, we measured serum 
acetylsalicylic acid as well as salicylic acid (Figs 1 and 2), and tried to 
identify the serum concentration required to inhibit COX activity and 
platelet aggregation. Although there was significant inter-individual 
variation, the inhibition of platelet aggregation, as well as the decrease of 
serum TXB2 level, in the early phase took place at a serum ASA 
concentration below the detection limit of <30 ng/mL. These results are 
broadly consistent with previous reports.7,22,31 Slow release, enteric-coated 
formulations may deliver ASA to the portal circulation at a slow enough rate 
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to allow substantial deacetylation of aspirin during its first pass through the 
liver. Ali et al have hypothesized that plasma ASA level, at least in the portal 
circulation, attains a bolus threshold required for maximum acetylation.7 
Our study supports this hypothesis.  
 Many of the previous studies were performed in the fasting state, 
but this may not always reflect the clinical situation. Patients may be 
admitted to hospital after a meal. The rate of gastrointestinal absorption of 
ASA is determined by the rate of dissolution into solution, luminal pH, and 
gastric emptying. Although most soluble ASA (pKa =3.5) is present in the 
non-ionized form at the stomach pH (pH 1.5 to 3.0), the solubility of ASA is 
low at the stomach pH. The pH shift in the upper small intestine decreases 
and increases the non-ionized form and solubility, respectively, and the net 
effect is to increase the absorption. So, delayed gastric emptying would 
reduce the rate of ASA absorption and consequently the effect on platelet 
aggregation. Therefore, this study was performed in volunteers who had the 
same lean breakfast 1 hr prior to ASA ingestion. Indeed, it is known that the 
tmax of enteric-coated ASA formulation is delayed from 3-4 hr to 9 hr.32 In this 
study, blood sampling was performed through 8 hr. The serum ASA 
concentrations in most volunteers were still increasing (Fig. 1), so tmax of 
ASA after ingestion of ECA might be greater than 8 hr. The tmax of ASA after 
ingestion of intact or chewed NBA (0.9-1.0 hr, Fig. 1 and Table 1) was also 
delayed compared with that observed in the fasting state (0.3-0.5 hr).22,28 
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Decrease of serum TXB2 and onset of platelet inhibition were delayed to 20 
min (Tables 3,4) compared with those in the fasting state (5-12 min).28 
Chewing NBA had little effect in accelerating ASA absorption or onset of 
action (Fig. 1, Tables 2,3). These observations may be ascribed to the effect of 
the fed state.  
 In conclusion, our quadruple-crossover clinical trial provides 
pharmacokinetic and pharmacodynamic evidence to support the 
recommendation of the Clinical Guidelines for Acute Myocardial Infarction 
that the initial dose of aspirin following admission to hospital should be 
chewed. Chewing ECA accelerated ASA absorption and onset of antiplatelet 
action even in the nonfasting state. Ingestion of either intact or chewed NBA 
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Serum Concentration-Time Profiles of Acetylsalicylic Acid after Ingestion of 
Intact and Chewed NBA and ECA 
Serum concentration of acetylsalicylic acid after ingestion of intact (open) 
and chewed (closed) NBA (circle) and ECA (triangle) were measured for 8 hrs. 




Serum Concentration-Time Profiles of Salicylic Acid after Ingestion of Intact 
and Chewed NBA and ECA 
Serum concentration of salicylic acid after ingestion of intact (open) and 
chewed (closed) NBA (circle) and ECA (triangle) were measured for 8 hrs. 
Each point represents the mean ± S.E.M. of 10-12 patients. 
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Table 1 
Pharmacokinetic Parameters of Acetylsalicylic Acid and Salicylic Acid after Ingestion of Intact and Chewed Non-coated 
Buffered ASA (NBA) and Enteric Coated ASA (ECA) 
 
Ingestion NBA ECA 
 intact chewed intact chewed 
Acetylsalicylic acid 
Cmax (ng/mL) 174 ± 156  223 ± 112  104 ± 291  198 ± 137  
tmax (hr) 0.9 ± 0.6  1.0 ± 0.6  ≥8  1.4 ± 1.0  
AUC0-8 (ng·hr/mL) 379 ± 310 491 ± 251  240 ± 326  480 ± 359  
MRT (hr) 1.9 ± 0.9  2.3 ± 0.5  6.8 ± 1.3*  2.4 ± 1.2  
Salicylic acid 
Cmax (μg/mL) 4.26 ± 1.30  4.21 ±1.18  2.77 ± 2.53  4.55 ± 1.55  
tmax (hr) 1.8 ± 0.8  2.1 ± 0.7  ≥8  2.6 ± 1.1  
AUC0-8 (μg·hr/mL) 19.2 ± 5.9  19.7 ± 6.7  6.9 ± 6.9*  19.7 ± 7.5  
MRT (hr) 4.2 ± 0.5  4.3 ± 0.4  6.8 ± 1.4*  4.4 ± 0.6  
 
Pharmacokinetic parameters were calculated by moment analysis as described in Materials and Methods. Data 
represent the mean ± S.D. of 10-12 patients.  Significant differences (p < 0.05) from other three groups are indicated 
by an asterisk (*); One-way ANOVA with Tukey’s post hoc test. 
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Table 2 
Effect of Ingestion of Intact and Chewed NBA and ECA on Serum Thromboxane B2 Level 
 
Ingestion NBA ECA 
 intact chewed intact chewed 
Time % of baseline % of baseline % of baseline % of baseline 
5 min 104.7 ± 59.0  142.6 ± 92.9  142.1 ± 71.7  126.3 ± 71.6  
10 91.3 ± 56.7  118.5 ± 72.4  101.9 ± 64.1  120.2 ± 50.8  
20 48.7 ± 28.0 *  57.6 ± 59.5  69.1 ± 47.4  47.3 ± 27.7 * 
30 86.4 ± 72.8  68.0 ± 57.1  150.0 ± 120.5  54.9 ± 43.7 * 
1 hr 27.0 ± 37.5 * 19.0 ± 15.7 * 77.7 ± 43.6  14.6 ± 16.0 * 
2 16.5 ± 21.5 * 12.8 ± 12.0 * 92.2 ± 65.1  10.9 ± 13.1 * 
4 5.0 ±  7.7 * 6.2 ±  7.0 * 49.8 ± 19.9  5.2 ±  6.0 * 
6 3.7 ±  5.3 * 4.5 ±  4.4 * 37.3 ± 36.8  3.3 ±  4.3 * 
8 3.4 ±  4.1 * 3.8 ±  3.6 * 22.1 ± 37.0 * 2.8 ±  3.9 * 
The maximum platelet aggregation was determined by aggregation tracing for 5 min for each blood sample obtained 
after ingestion of ASA. Inhibition of platelet aggregation by ASA was expressed as a percent of the maximum platelet 
aggregation determined before ASA ingestion (baseline) for each patient. Each value represents the mean ± S.D. of 
10-12 patients. A significant difference (p < 0.05) from the baseline is indicated by an asterisk (*); One-way ANOVA 
with Dunnett’s post hoc test. 
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Table 3 
Effect of Ingestion of Intact and Chewed NBA and ECA on Platelet Aggregation Induced with 1 μg/mL Collagen 
 
Ingestion NBA ECA 
 intact chewed intact chewed 
Time % of baseline % of baseline % of baseline % of baseline 
5 min 79.2 ± 20.3  87.0 ± 36.6  67.4 ± 26.0  68.8 ± 31.4  
10  77.6 ± 38.3  94.6 ± 43.6  88.5 ± 32.2  88.7 ± 40.4  
20  47.6 ± 43.9 *  60.4 ± 36.8 * 74.0 ± 24.1  56.3 ± 51.0 * 
30  53.2 ± 45.9 * 51.9 ± 47.8 * 85.0 ± 27.8  47.2 ± 43.3 * 
1 hr 26.5 ± 28.6 * 35.1 ± 33.2 * 66.5 ± 33.3  24.7 ± 36.9 * 
2 14.5 ± 19.9 * 19.4 ± 12.2 * 73.9 ± 28.7  29.8 ± 37.7 * 
4 12.4 ± 17.8 * 12.5 ± 12.6 * 46.8 ± 42.3 * 16.7 ± 22.4 * 
6 7.7 ± 10.6 * 7.7 ± 11.5 * 31.2 ± 44.5 * 11.2 ± 18.2 * 
8 7.4 ± 13.1 * 5.2 ±  6.9 * 15.8 ± 23.5 * 9.4 ± 17.5 * 
 
The maximum platelet aggregation induced with 1 μg/mL collagen was determined by aggregation tracing for 5 min for 
each blood sample obtained after ingestion of ASA. Inhibition of platelet aggregation by ASA was expressed as a 
percentage of the maximum platelet aggregation in the baseline condition for each patient. Each value represents the 
mean ± S.D. of 8-12 patients. A significant difference (p < 0.05) from the baseline is indicated by an asterisk (*); 
One-way ANOVA with Dunnett’s post hoc test. 
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Table 4 
Effect of Ingestion of Intact and Chewed NBA and ECA on Platelet Aggregation Induced with 2 μM ADP 
 
Ingestion NBA ECA 
 intact chewed intact chewed 
Time % of baseline % of baseline % of baseline % of baseline 
5 min 95.4 ± 26.1  103.5 ± 36.6  94.7 ± 18.1  95.6 ± 18.7  
10  73.9 ± 19.3  86.6 ± 31.6  86.9 ± 17.8  90.8 ± 21.1  
20  85.5 ± 28.7   84.7 ± 39.7  77.9 ± 21.0  83.1 ± 26.0  
30  82.0 ± 15.9  86.0 ± 25.1  79.3 ± 22.8  81.8 ± 26.2  
1 hr 86.3 ± 21.0  82.0 ± 25.9  95.0 ± 27.9  81.8 ± 27.0  
2 64.4 ± 23.0 * 76.1 ± 12.3  79.8 ± 30.9  79.7 ± 20.0  
4 69.5 ± 24.0 * 76.3 ± 23.9  91.9 ± 23.0  80.3 ± 15.1  
6 75.6 ± 17.7 * 67.9 ± 24.2 * 91.8 ± 20.4  73.4 ± 25.5 * 
8 76.6 ± 17.4  73.8 ± 23.7  79.6 ± 20.3  68.1 ± 28.3 * 
 
The maximum platelet aggregation induced with 2 μM ADP was determined as described in the legend of Table 3. Each 
value represents the mean ± S.D. of 8-12 patients. A significant difference (p < 0.05) from the baseline is indicated by an 
asterisk (*); One-way ANOVA with Dunnett’s post hoc test. 


